Welcome to LookChem.com Sign In|Join Free

CAS

  • or

192189-07-4

Post Buying Request

192189-07-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

192189-07-4 Usage

Uses

1-Boc-3-iodoindole is used as a pharmaceutical intermediate and also used in ceramic manufacturing industry.

Check Digit Verification of cas no

The CAS Registry Mumber 192189-07-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,2,1,8 and 9 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 192189-07:
(8*1)+(7*9)+(6*2)+(5*1)+(4*8)+(3*9)+(2*0)+(1*7)=154
154 % 10 = 4
So 192189-07-4 is a valid CAS Registry Number.
InChI:InChI=1/C13H14INO2/c1-13(2,3)17-12(16)15-8-10(14)9-6-4-5-7-11(9)15/h4-8H,1-3H3

192189-07-4 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (H27022)  1-Boc-3-iodoindole, 95%   

  • 192189-07-4

  • 250mg

  • 703.0CNY

  • Detail
  • Alfa Aesar

  • (H27022)  1-Boc-3-iodoindole, 95%   

  • 192189-07-4

  • 1g

  • 1137.0CNY

  • Detail

192189-07-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name tert-butyl 3-iodoindole-1-carboxylate

1.2 Other means of identification

Product number -
Other names tert-butyl 3-iodo-1H-1-indolecarboxylate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:192189-07-4 SDS

192189-07-4Relevant articles and documents

Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 6. 2-Indol-3-yl- and 2-azaindol-3-yl- dipyridodiazepinones

Kelly,McNeil,Rose,David,Shih,Grob

, p. 2430 - 2433 (1997)

Modification of the non-nucleoside inhibitor of HIV-1 reverse transcriptase nevirapine (Viramune) by incorporation of a 2-indolyl substituent confers activity against several mutant forms of the enzyme.

INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER

-

Page/Page column 71-72; 80; 88; 145, (2022/02/06)

The present invention relates to indole derivatives of formula (I') as CK2 inhibitor and pharmaceutical compositions comprising the same. The present invention further relates to the use of such compounds of formula (I) for use for preventing and/or treating a cancer.

Small-molecule anti-HIV-1 agents based on HIV-1 capsid proteins

Kobayakawa, Takuya,Yokoyama, Masaru,Tsuji, Kohei,Fujino, Masayuki,Kurakami, Masaki,Boku, Sayaka,Nakayama, Miyuki,Kaneko, Moemi,Ohashi, Nami,Kotani, Osamu,Murakami, Tsutomu,Sato, Hironori,Tamamura, Hirokazu

, p. 1 - 14 (2021/02/06)

The capsid of human immunodeficiency virus type 1 (HIV-1) is a shell that encloses viral RNA and is highly conserved among many strains of the virus. It forms a conical structure by assembling oligomers of capsid (CA) proteins. CA dysfunction is expected to be an important target of suppression of HIV-1 replication, and it is important to understand a new mechanism that could lead to the CA dysfunction. A drug targeting CA however, has not been developed to date. Hydrophobic interactions between two CA molecules via Trp184/Met185 in CA were recently reported to be important for stabilization of the multimeric structure of CA. In the present study, a small molecule designed by in silico screening as a dipeptide mimic of Trp184 and Met185 in the interaction site, was synthesized and its significant anti-HIV-1 activity was confirmed. Structure activity relationship (SAR) studies of its derivatives were performed and provided results that are expected to be useful in the future design and development of novel anti-HIV agents targeting CA.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 192189-07-4